Stock comparison
Edwards Lifesciences
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
EW
Edwards Lifesciences
Market cap
$49.39B
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | EW | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 61C | 71B | UTHR |
| Benjamin Graham | 89A | 76B | EW |
| Philip Fisher | 62C | 76B | UTHR |
| Peter Lynch | 26F | 62C | UTHR |
| Joel Greenblatt | 54C | 46D | EW |
| Charlie Munger | 71C | 64C | EW |
| Terry Smith | 70B | 64C | EW |
Side-by-side metrics
| Metric | EW | UTHR |
|---|---|---|
| Market cap | $49.39B | $24.13B |
| P/E (TTM) | 43.2x | 19.2x |
| EV/EBIT | 27.6x | 15.2x |
| ROIC (TTM) | 12.06% | 18.81% |
| Gross margin | 78.01% | 86.58% |
| Net margin | 17.34% | 40.61% |
| Revenue CAGR 5y | 3.77% | 17.22% |
| EPS CAGR 5y | -6.52% | 29.84% |
| Debt / Equity | 0.1x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
EW leads on
- Market cap$49.39Bvs $24.13B+51%
UTHR leads on
- EPS CAGR 5y29.84%vs -6.52%+122%
- Debt / Equity-vs 0.1x+100%
- Revenue CAGR 5y17.22%vs 3.77%+78%
- Net margin40.61%vs 17.34%+57%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.